Clinical Trial

Combined Gastrointestinal Decontamination in Acute Severe Poisoning

Study acronym: DIMREATOX
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Gastrointestinal absorption of high dose medication (toxicant) ingested under solid form for suicidal purposes, is prolonged in patients who need intensive care admission and mechanical ventilation. This is due to the large ingested amounts, slowed blood circulation in the digestive system due to low blood pressure, and the formation of conglomerates of pills (pharmacobezoars). We make the hypothesis that combined decontamination of the digestive system with activated charcoal plus polyethylene glycol may reduce absorption of the ingested toxicant compared with standard care. Two hundred patients requiring admission to intensive care and mechanical ventilation due to the effect of the ingested toxicant, will be included in a 1:1 randomized fashion over 24 months in the intervention group receiving combined decontamination and standard care group receiving activated charcoal according to guidelines. The main objective is to show a decrease in the concentration of the toxicant after 24h of randomization.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-07
notable Primary completion pushed: 2028-03 -> 2028-06-24 2026-07-07
minor Completion pushed: 2028-04 -> 2028-07 2026-07-07
Trial Details
NCT Number NCT07201311
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Severe Poisoning With Cardiotropic or Psychotropic Drug, Admission to Intensive Care
Enrollment 200 participants
Start Date 2026-06-24
Primary Completion 2028-06-24 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-06